SGMO

Sangamo Therapeutics Inc

0.51

0.03+5.65%

After Hours: 0.5078 -0.00 -0.47%19:57 07/18 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.4950/0.4829

TODAY RANGE0.4829-0.5195

VOL5.04M

MARKET CAP125.20M

52 WEEK RANGE0.3723-3.179

AVG VOL (3M)4.86M

% TURNOVER2.06%

TURNOVER--

P/E (TTM)-1.3304

% RANGE7.56%

EPS(TTM)-0.3835

P/E(FORWARD)-1.2324

P/B23.40

BVPS0.0218

DIVIDEND--

P/S1.878

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP121.71M

SHARES OUTSTANDING245.40M

NEXT EARNINGS08/04-08/08

FREE FLOAT238.55M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·06/30 16:10
Analysts’ Top Healthcare Picks: Sangamo Biosciences (SGMO), Alpha Cognition Inc (ACOG)
TipRanks·06/30 12:20
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)
TipRanks·06/27 16:15
Cautious Optimism for Sangamo Biosciences Amid Promising Fabry Program Data and Ongoing Business Developments
TipRanks·06/25 11:36
Truist Financial Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)
Dow Jones·06/24 16:47
Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Benzinga·06/24 16:40
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
TipRanks·06/24 16:35
Sangamo Biosciences (SGMO) Receives a Buy from H.C. Wainwright
Seeking Alpha·06/24 12:46
Sangamo rises after trial data for Fabry disease therapy
NASDAQ·06/24 12:43
Sangamo Therapeutics Reports Positive Data From Phase 1/2 STAAR Study In Fabry Disease
TipRanks·06/24 12:29
Sangamo Announces Positive Results for Fabry Disease Therapy
TipRanks·06/24 12:20
Sangamo announces topline results from STAAR study
Benzinga·06/24 12:10
Sangamo Therapeutics Announces Topline Results From Registrational Phase 1/2 STAAR Of ST-920 In Fabry Disease; Intends To Submit Biologics License Application In 2026
Reuters·06/24 12:05
SANGAMO THERAPEUTICS INC - STAAR STUDY SHOWS POSITIVE MEAN ANNUALIZED EGFR SLOPE AT 52 WEEKS
TipRanks·06/16 20:32
Sangamo Biosciences Approves Amendments to Equity Plan
TipRanks·05/28 13:35
Sangamo Biosciences: Promising Strategic Milestones and Potential Value Creation Drive Buy Rating

Same Industry

Name/Symbol

Change%

Price

Sangamo Therapeutics Inc

SGMO

+5.65%

0.5102

Regeneron Pharmaceuticals

REGN

-1.36%

542.52

Entero Therapeutics

ENTO

-0.08%

0.4728

BIONTECH

BNTX

-0.92%

110.02

United Therapeutics Corp.

UTHR

-1.79%

292.01

Vertex Pharmaceuticals Inc

VRTX

-0.75%

459.81

Siga Technologie

SIGA

-1.34%

6.61

Moderna

MRNA

-2.92%

31.26

Charles Riv Labs Intl Inc

CRL

-1.42%

154.48

Medpace Holdings

MEDP

-2.28%

311.87

Talphera Inc

TLPH

-4.67%

0.4099

ICON PLC

ICLR

-2.27%

143.54

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-1.60%

160.63

MOLECULAR PARTNERS AG

MOLN

-1.51%

3.60

Arcturus Therape

ARCT

-0.30%

13.50

Gilead Sciences Inc

GILD

-0.53%

108.22

PRA Health

PRAH

165.21

Incyte Corp

INCY

-1.57%

67.86

Aptevo Therapeutics Inc

APVO

+1.68%

3.03

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.